CHICAGO TRUST Co NA Buys 7,373 Shares of DexCom, Inc. (NASDAQ:DXCM)

CHICAGO TRUST Co NA boosted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 67.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,236 shares of the medical device company’s stock after acquiring an additional 7,373 shares during the period. CHICAGO TRUST Co NA’s holdings in DexCom were worth $1,418,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the company. Versant Capital Management Inc acquired a new position in shares of DexCom in the 4th quarter valued at $25,000. Riverview Trust Co lifted its stake in DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after purchasing an additional 232 shares during the period. RPg Family Wealth Advisory LLC acquired a new stake in DexCom during the third quarter valued at approximately $57,000. Covestor Ltd boosted its holdings in DexCom by 53.7% during the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after purchasing an additional 335 shares in the last quarter. Finally, Blue Trust Inc. raised its holdings in shares of DexCom by 101.9% in the 3rd quarter. Blue Trust Inc. now owns 1,779 shares of the medical device company’s stock worth $119,000 after buying an additional 898 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Trading Down 2.1 %

Shares of DXCM stock traded down $1.60 on Monday, hitting $76.16. The stock had a trading volume of 1,732,142 shares, compared to its average volume of 2,792,768. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The company has a fifty day moving average price of $76.93 and a two-hundred day moving average price of $78.84. The firm has a market cap of $29.75 billion, a P/E ratio of 45.61, a PEG ratio of 2.36 and a beta of 1.12. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on DXCM shares. Raymond James dropped their price objective on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research note on Friday, October 25th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. JPMorgan Chase & Co. lifted their target price on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Leerink Partners reduced their target price on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Finally, Sanford C. Bernstein lifted their price objective on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $98.00.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now directly owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.30% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.